Comparison of QFT-Plus and QFT-GIT tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects

QFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube (QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with peptides that may stimulate CD8+ T cells. This study evaluated the diagnostic performance of QFT-Plus and compared it with that of QFT-GIT. QFT-Pl...

Full description

Saved in:
Bibliographic Details
Published inJournal of thoracic disease Vol. 11; no. 12; pp. 5210 - 5217
Main Authors Hong, Ji Young, Park, So Yeong, Kim, Ahreum, Cho, Sang-Nae, Hur, Yun-Gyoung
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 01.12.2019
Subjects
Online AccessGet full text
ISSN2072-1439
2077-6624
DOI10.21037/jtd.2019.12.11

Cover

Loading…
Abstract QFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube (QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with peptides that may stimulate CD8+ T cells. This study evaluated the diagnostic performance of QFT-Plus and compared it with that of QFT-GIT. QFT-Plus and QFT-GIT tests were performed in 33 patients with active tuberculosis (TB) and 57 healthy controls including subjects with latent TB infection (LTBI). Positivity and negativity of IFN-γ responses were compared between tests, and total concordance of the outcome was analyzed. Positive and negative outcomes of QFT-Plus and QFT-GIT tests showed substantial agreement (91.1%, kappa=0.8). The sensitivity and the specificity of QFT-Plus (93.9% sensitivity, 92.6% specificity) were similar with those of QFT-GIT (93.9% sensitivity, 100% specificity). Of eight discordant results, five (5.56%) and three (3.3%) were positive in QFT-GIT alone and QFT-plus alone, respectively. Reactivity in the TB2 tube contributes to the difference between QFT-GIT and QFT-Plus. Median IFN-γ production in TB2 (10.0 IU/mL in TB, 3.850 IU/mL in LTBI, P=0.001) is significantly higher in the TB group than the LTBI group. The QFT-Plus did not clearly discriminate between active TB and latent TB, although it showed significantly lower IFN-γ concentrations compared with the QFT-GIT in individuals with LTBI (3.850 7.205 IU/mL). Similar accuracy of detecting infection was observed for QFT-Plus and QFT-GIT tests in immunocompetent patients and healthy controls, including those with LTBI. Improved efficacy for identifying infection was not found with the QFT-Plus, but further studies in a larger population may confirm the clinical significance of positive response in the TB2 tube of QFT-Plus.
AbstractList QFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube (QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with peptides that may stimulate CD8+ T cells. This study evaluated the diagnostic performance of QFT-Plus and compared it with that of QFT-GIT. QFT-Plus and QFT-GIT tests were performed in 33 patients with active tuberculosis (TB) and 57 healthy controls including subjects with latent TB infection (LTBI). Positivity and negativity of IFN-γ responses were compared between tests, and total concordance of the outcome was analyzed. Positive and negative outcomes of QFT-Plus and QFT-GIT tests showed substantial agreement (91.1%, kappa=0.8). The sensitivity and the specificity of QFT-Plus (93.9% sensitivity, 92.6% specificity) were similar with those of QFT-GIT (93.9% sensitivity, 100% specificity). Of eight discordant results, five (5.56%) and three (3.3%) were positive in QFT-GIT alone and QFT-plus alone, respectively. Reactivity in the TB2 tube contributes to the difference between QFT-GIT and QFT-Plus. Median IFN-γ production in TB2 (10.0 IU/mL in TB, 3.850 IU/mL in LTBI, P=0.001) is significantly higher in the TB group than the LTBI group. The QFT-Plus did not clearly discriminate between active TB and latent TB, although it showed significantly lower IFN-γ concentrations compared with the QFT-GIT in individuals with LTBI (3.850 7.205 IU/mL). Similar accuracy of detecting infection was observed for QFT-Plus and QFT-GIT tests in immunocompetent patients and healthy controls, including those with LTBI. Improved efficacy for identifying infection was not found with the QFT-Plus, but further studies in a larger population may confirm the clinical significance of positive response in the TB2 tube of QFT-Plus.
QFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube (QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with peptides that may stimulate CD8+ T cells. This study evaluated the diagnostic performance of QFT-Plus and compared it with that of QFT-GIT.BACKGROUNDQFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube (QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with peptides that may stimulate CD8+ T cells. This study evaluated the diagnostic performance of QFT-Plus and compared it with that of QFT-GIT.QFT-Plus and QFT-GIT tests were performed in 33 patients with active tuberculosis (TB) and 57 healthy controls including subjects with latent TB infection (LTBI). Positivity and negativity of IFN-γ responses were compared between tests, and total concordance of the outcome was analyzed.METHODSQFT-Plus and QFT-GIT tests were performed in 33 patients with active tuberculosis (TB) and 57 healthy controls including subjects with latent TB infection (LTBI). Positivity and negativity of IFN-γ responses were compared between tests, and total concordance of the outcome was analyzed.Positive and negative outcomes of QFT-Plus and QFT-GIT tests showed substantial agreement (91.1%, kappa=0.8). The sensitivity and the specificity of QFT-Plus (93.9% sensitivity, 92.6% specificity) were similar with those of QFT-GIT (93.9% sensitivity, 100% specificity). Of eight discordant results, five (5.56%) and three (3.3%) were positive in QFT-GIT alone and QFT-plus alone, respectively. Reactivity in the TB2 tube contributes to the difference between QFT-GIT and QFT-Plus. Median IFN-γ production in TB2 (10.0 IU/mL in TB, 3.850 IU/mL in LTBI, P=0.001) is significantly higher in the TB group than the LTBI group. The QFT-Plus did not clearly discriminate between active TB and latent TB, although it showed significantly lower IFN-γ concentrations compared with the QFT-GIT in individuals with LTBI (3.850 vs. 7.205 IU/mL).RESULTSPositive and negative outcomes of QFT-Plus and QFT-GIT tests showed substantial agreement (91.1%, kappa=0.8). The sensitivity and the specificity of QFT-Plus (93.9% sensitivity, 92.6% specificity) were similar with those of QFT-GIT (93.9% sensitivity, 100% specificity). Of eight discordant results, five (5.56%) and three (3.3%) were positive in QFT-GIT alone and QFT-plus alone, respectively. Reactivity in the TB2 tube contributes to the difference between QFT-GIT and QFT-Plus. Median IFN-γ production in TB2 (10.0 IU/mL in TB, 3.850 IU/mL in LTBI, P=0.001) is significantly higher in the TB group than the LTBI group. The QFT-Plus did not clearly discriminate between active TB and latent TB, although it showed significantly lower IFN-γ concentrations compared with the QFT-GIT in individuals with LTBI (3.850 vs. 7.205 IU/mL).Similar accuracy of detecting Mycobacterium tuberculosis infection was observed for QFT-Plus and QFT-GIT tests in immunocompetent patients and healthy controls, including those with LTBI. Improved efficacy for identifying M. tuberculosis infection was not found with the QFT-Plus, but further studies in a larger population may confirm the clinical significance of positive response in the TB2 tube of QFT-Plus.CONCLUSIONSSimilar accuracy of detecting Mycobacterium tuberculosis infection was observed for QFT-Plus and QFT-GIT tests in immunocompetent patients and healthy controls, including those with LTBI. Improved efficacy for identifying M. tuberculosis infection was not found with the QFT-Plus, but further studies in a larger population may confirm the clinical significance of positive response in the TB2 tube of QFT-Plus.
Author Hong, Ji Young
Cho, Sang-Nae
Park, So Yeong
Kim, Ahreum
Hur, Yun-Gyoung
Author_xml – sequence: 1
  givenname: Ji Young
  surname: Hong
  fullname: Hong, Ji Young
– sequence: 2
  givenname: So Yeong
  surname: Park
  fullname: Park, So Yeong
– sequence: 3
  givenname: Ahreum
  surname: Kim
  fullname: Kim, Ahreum
– sequence: 4
  givenname: Sang-Nae
  surname: Cho
  fullname: Cho, Sang-Nae
– sequence: 5
  givenname: Yun-Gyoung
  surname: Hur
  fullname: Hur, Yun-Gyoung
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32030238$$D View this record in MEDLINE/PubMed
BookMark eNp1Uc1rHCEclZLSpGnOvRWPvczEn-7M6KVQliYNTWgCexd1NHWZ0a06gf73dTdJaQsRwa_3Ie-9RUchBovQeyAtBcKG820ZW0pAtEBbgFfohJJhaPqero4Oe9rAioljdJbzltTRE0qH4Q06ZpQwQhk_QQ_rOO9U8jkGHB2-u9g0t9OSsQrj4XB5tcHF5pKxiwmPXt2HmH3eY29aXBZtk1mmw5UPzpriq5Cvc56XEE0Vt8WGgr_FZFXAedHbCsrv0GunpmzPntZTtLn4sll_ba6_X16tP183hglWGmCEW9B2NYycMDWIzgFnXS_MYAAoWSmhhdHAiQFCXaeFVZo7IpwZQY_sFH16lN0terajqT9JapK75GeVfsmovPz3Jfgf8j4-yF5wTgivAh-fBFL8udQc5OyzsdOkgo1LlpR1tGesB1GhH_72-mPynHUFdI8Ak2LOyTppfFH7wKq1nyQQeahV1lrlvlYJVAJU3vl_vGfplxi_AeBlpnw
CitedBy_id crossref_primary_10_1128_JCM_01950_19
crossref_primary_10_3389_fmicb_2021_745592
crossref_primary_10_1016_j_vetimm_2020_110152
crossref_primary_10_1186_s12879_023_08008_2
crossref_primary_10_1136_bmjophth_2020_000663
crossref_primary_10_1080_24745332_2022_2036503
crossref_primary_10_1093_cid_ciad030
crossref_primary_10_1016_j_jctube_2024_100504
crossref_primary_10_1007_s00296_023_05320_7
crossref_primary_10_1080_24745332_2023_2226001
crossref_primary_10_1186_s12889_025_21954_7
crossref_primary_10_1016_j_jctube_2021_100223
crossref_primary_10_1016_j_medmic_2024_100116
crossref_primary_10_1128_spectrum_01870_21
crossref_primary_10_1093_cid_ciaa1822
crossref_primary_10_1093_rheumatology_kead361
crossref_primary_10_1515_cclm_2023_0293
ContentType Journal Article
Copyright 2019 Journal of Thoracic Disease. All rights reserved.
2019 Journal of Thoracic Disease. All rights reserved. 2019 Journal of Thoracic Disease.
Copyright_xml – notice: 2019 Journal of Thoracic Disease. All rights reserved.
– notice: 2019 Journal of Thoracic Disease. All rights reserved. 2019 Journal of Thoracic Disease.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.21037/jtd.2019.12.11
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2077-6624
EndPage 5217
ExternalDocumentID PMC6988008
32030238
10_21037_jtd_2019_12_11
Genre Journal Article
GroupedDBID 53G
AAKDD
AAWTL
AAYXX
ACGFO
ADBBV
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BMSDO
CITATION
DIK
GX1
HYE
OK1
RPM
NPM
7X8
5PM
ID FETCH-LOGICAL-c393t-1308e1be47d803a795f183569c7c11204a9b9cb180c102f5b9eab8f09fcd1bd3
ISSN 2072-1439
IngestDate Thu Aug 21 13:43:20 EDT 2025
Fri Sep 05 12:50:34 EDT 2025
Mon Jul 21 06:04:04 EDT 2025
Thu Apr 24 23:12:40 EDT 2025
Tue Jul 01 04:37:39 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords QFT-Plus
Diagnosis
QuantiFERON-TB Gold In-Tube (QFT-GIT)
tuberculosis (TB)
Mycobacterium tuberculosis (M. tb)
latent tuberculosis infection (LTBI)
Language English
License 2019 Journal of Thoracic Disease. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c393t-1308e1be47d803a795f183569c7c11204a9b9cb180c102f5b9eab8f09fcd1bd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: (I) Conception and design: YG Hur; (II) Administrative support: JY Hong, YG Hur; (III) Provision of study materials or patients: JY Hong, SN Cho, YG Hur; (IV) Collection and assembly of data: JY Hong, SY Park, A Kim, YG Hur; (V) Data analysis and interpretation: JY Hong, A Kim, YG Hur; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
OpenAccessLink https://jtd.amegroups.com/article/viewFile/34058/pdf
PMID 32030238
PQID 2352633619
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6988008
proquest_miscellaneous_2352633619
pubmed_primary_32030238
crossref_citationtrail_10_21037_jtd_2019_12_11
crossref_primary_10_21037_jtd_2019_12_11
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-12-00
2019-Dec
20191201
PublicationDateYYYYMMDD 2019-12-01
PublicationDate_xml – month: 12
  year: 2019
  text: 2019-12-00
PublicationDecade 2010
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Journal of thoracic disease
PublicationTitleAlternate J Thorac Dis
PublicationYear 2019
Publisher AME Publishing Company
Publisher_xml – name: AME Publishing Company
SSID ssj0000602277
Score 2.3004324
Snippet QFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube (QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 5210
SubjectTerms Original
Title Comparison of QFT-Plus and QFT-GIT tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/32030238
https://www.proquest.com/docview/2352633619
https://pubmed.ncbi.nlm.nih.gov/PMC6988008
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLVgSIgXxH3dABmJB6QoJYlz8-M0rRRYC4hMKk9R7DisqEpQm_DAr-fzJbeySYOXKHXTpOo5_Xz8-fMxQq9BBXh5TIXtQ3dp-4xRO4sEt11GSeAwOXEkVyMvluH8wv-wClZ9ua1aXVKzKf995bqS_0EV2gBXuUr2H5DtbgoNcA74whEQhuONMD4dbiJofZkl9udNo02X5Yt37xMLlGStLBdkllUW1Wn_kcXUqhsmtrzZqKa2JkvVPa7lmpGKG0VdWx-rrczX7xomkza7a_RsfQls4mu-P-czb4t-15YKLf2kla7S_lpZ30TVt5v9nU-AZMYmQlUfVDp_XX63l5kY5ipcOqj7UCHNcyLPBoVGR_HXHfLMG0RTkBbOVWHeM04BP2rp9epSmdA1dxkZai8_pbOL8_M0OVslt9EdD0YSziChoztr6aEoF9V3300bQKlnvB0_Yaxd_hqQ7NfVDoRK8gDdN4jgE02Xh-iWKB-huwtTQ_EY_epZg6sCt6zBwBpsWIMVazCwBneskdcupnjIGtyxBs7wHmuwZg1uWfMEJbOz5HRum903bE4oqW0QN7FwmfCjPHZIFtGggPAfhJRHHES642eUUc7c2OEgUouAUZGxuHBowXOX5eQpOiirUhwiLIKw8LMMpKTIYHxcUE58n7mEQVQoSJ5P0LT9WVNunOnlBimbFEaoCocUcEglDqnrwZh1gt50H_ipTVmuv_RVi1MKgVPOhmWlqJpd6smdIQgJXTpBzzRu3c2I58jNtOIJikaIdhdIU_bxO-X6UpmzhxR6RCc-usFzj9G9_k_yHB3U20a8AIlbs5eKpH8AO_SqdQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+QFT-Plus+and+QFT-GIT+tests+for+diagnosis+of+M.+tuberculosis+infection+in+immunocompetent+Korean+subjects&rft.jtitle=Journal+of+thoracic+disease&rft.au=Hong%2C+Ji+Young&rft.au=Park%2C+So+Yeong&rft.au=Kim%2C+Ahreum&rft.au=Cho%2C+Sang-Nae&rft.date=2019-12-01&rft.issn=2072-1439&rft.volume=11&rft.issue=12&rft.spage=5210&rft_id=info:doi/10.21037%2Fjtd.2019.12.11&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-1439&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-1439&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-1439&client=summon